GlassScriptPhysician profile
William Zamora
NPI 1053305185
$3,573.36
in general payments reported to CMS, 2019-2025
28 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $441 · 2021: $887 · 2022: $633 · 2023: $244 · 2024: $496 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.77 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $781.42 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $519.22 | 2020-2024 | Farxiga |
| Eisai INC. | $243.18 | 2021-2025 | |
| Amgen INC. | $218.67 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $158.88 | 2025 | Optimizer |
| Stemline Therapeutics INC. | $142.23 | 2025 | Orserdu |
| Boston Scientific Corporation | $137.96 | 2024 | |
| Medtronic, INC. | $129.61 | 2025 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $128.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $124.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.90 | 2021 | |
| Lilly USA, LLC | $121.91 | 2020-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $116.19 | 2020 | |
| Shire North American Group INC | $115.99 | 2019 | |
| Rare Disease Therapeutics, INC. | $96.84 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.50 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $74.53 | 2020-2022 | |
| Hologic Sales and Service, LLC | $45.62 | 2023-2024 | Aptima |
| Abiomed | $32.38 | 2023-2024 | Impella |
| Amarin Pharma, INC. | $30.13 | 2020 | |
| Abbvie INC. | $24.55 | 2021-2022 | |
| Lucid Diagnostics INC. | $21.27 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.39 | 2021 | |
| Abbott Laboratories | $19.86 | 2023 | Freestyle Libre 2 |
| Teleflex LLC | $14.72 | 2021 | |
| Exact Sciences Corporation | $14.16 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $13.37 | 2024 | Flucelvax, Fluad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Zamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.